Non-Small Cell Lung Cancer- Localized and Unresectable

No Trials Currently Available

Correlatives

Inoperable Stage I/II

IRB#20077
A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

IRB#19566
A Phase II Study of Rucaparib in Patients with Genomic LOH HIGH and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NSCLC (LUNG-MAP SUB-STUDY)

Inoperable Stage IIIA/B

IRB#20077
A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

IRB#19566
A Phase II Study of Rucaparib in Patients with Genomic LOH HIGH and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NSCLC (LUNG-MAP SUB-STUDY)

CROSS-DISEASE TRIALS:

IRB# 19992
EAY131 (MATCH)

http://www.ohsu.edu/research/rda/so/knight.php